O. Altundag Et Al. , "HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients," LUNG CANCER , vol.49, no.2, pp.279-280, 2005
Altundag, O. Et Al. 2005. HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients. LUNG CANCER , vol.49, no.2 , 279-280.
Altundag, O., Altundag, K., Ozcakar, B., & Silay, Y., (2005). HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients. LUNG CANCER , vol.49, no.2, 279-280.
Altundag, O Et Al. "HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients," LUNG CANCER , vol.49, no.2, 279-280, 2005
Altundag, O Et Al. "HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients." LUNG CANCER , vol.49, no.2, pp.279-280, 2005
Altundag, O. Et Al. (2005) . "HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients." LUNG CANCER , vol.49, no.2, pp.279-280.
@article{article, author={O Altundag Et Al. }, title={HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients}, journal={LUNG CANCER}, year=2005, pages={279-280} }